1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Tryp Therapeutics Inc.

Tryp Therapeutics Inc.

TRYP.CN
Tryp Therapeutics Inc.CA flagCanadian Securities Exchange
0.06
CAD
- -
- -
5.79MMarket Cap
Tryp Therapeutics Inc.
TRYP.CN
(Canadian Securities Exchange)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
TTM
FRC
- -
- -
- -
- -
- -
Revenue per Share
-0.01
-0.14
-0.1
-0.05
-0.05
Basic EPS, GAAP
- -
-0.09
-0.08
-0.04
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
0.03
0.02
-0.03
-0.08
-0.09
Book Value per Share
0.01
0.07
0.01
-0.04
-0.05
Tangible Book Value per Share
66
58
78
96
96
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
-8
-7
-5
-5
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
1
4
1
-1
-5
Working Capital
- -
- -
- -
2
- -
LT Debt
2
4
1
-4
-5
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-577.93
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
May'23
Aug'23
Nov'24
ST Debt
- -
- -
5
LT Borrowings
1
2
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
96
96
96
Market Capitalization
8
8
5

Working Capital

FRC

•

in mil. unless spec.
May'23
Aug'23
Nov'24
Total Current Assets
1
- -
2
Cash, Cash Equivalents & STI
1
- -
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
7
Payables & Accruals
2
2
2
ST Debt
- -
- -
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-428.92%
Free Cash Flow
- -
- -
-38.96%
Net Income, GAAP
- -
- -
-29.73%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.05
-0.03
-0.01
- -
-0.1
2023
-0.02
-0.01
-0.01
- -
-0.05
2024
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Clovis Oncology, Inc. (CLVS)
immatics biotechnologies GmbH (IMTXW)
SinoMab BioScience Limited (3681.HK)
Antengene Corporation Limited (6996.HK)
Immuno-Biological Laboratories Co., Ltd. (4570.T)
Aerpio Pharmaceuticals, Inc. (ARPO)
Business
I will now gather detailed and up-to-date information specifically on Tryp Therapeutics Inc. regarding its main products, services, and any recent major company changes including partnerships, funding, acquisitions, or new offerings from recent publicly available sources.